Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy
Open Access
- 13 April 2017
- journal article
- editorial
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 17 (6) , 659-661
Abstract
(2017). Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy. Expert Opinion on Biological Therapy: Vol. 17, No. 6, pp. 659-661.Keywords
This publication has 17 references indexed in Scilit:
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaMolecular Therapy, 2017
- At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignanciesJournal of Leukocyte Biology, 2016
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsJournal of Clinical Investigation, 2016
- CAR models: next-generation CAR modifications for enhanced T-cell functionMolecular Therapy-Oncolytics, 2016
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology, 2015
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Adoptive Immunotherapy for Cancer or VirusesAnnual Review of Immunology, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- The Basic Principles of Chimeric Antigen Receptor DesignCancer Discovery, 2013